🔍

SAILIFE - Sai Life

📊 NSE: SAILIFE 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/14/2025 12:38

📢 Recent Corporate Announcements

Sai Life Sciences to Attend Investec CDMO Day on March 13, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 07 Mar 2026, 11:08 AM

Sai Life Sciences Limited has scheduled a group meeting with Investec Capital Services (India) for their 'CDMO Day' on March 13, 2026. The meeting will be held in Hyderabad and involves interactions with institutional investors and analysts. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be discussed during the session. Furthermore, no new investor presentation will be introduced during this specific event.

Meeting scheduled for March 13, 2026, in Hyderabad.
Participation in the Investec Capital Services (India) CDMO Day event.
Format of the interaction is a group meeting with analysts and investors.
Company confirmed that no new presentation or UPSI will be shared.

💡 This is a routine investor relations event; shareholders should monitor for any post-event disclosures, though no major immediate impact is expected.

ICRA Assigns [ICRA]AA (Stable) and [ICRA]A1+ Ratings to Sai Life Sciences' Rs 768.60 Cr Debt

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 26 Feb 2026, 05:12 PM

ICRA Limited has assigned high-grade credit ratings to Sai Life Sciences Limited for its total debt facilities of Rs 768.60 crore. The long-term fund-based facilities of Rs 550 crore received an [ICRA]AA (Stable) rating, while short-term non-fund-based facilities of Rs 218.60 crore were assigned [ICRA]A1+. These ratings reflect a strong credit profile and a high degree of safety regarding the timely servicing of financial obligations. The facilities are spread across major lenders including State Bank of India, IndusInd Bank, and Bank of Baroda.

Assigned [ICRA]AA (Stable) rating for Rs 550.00 crore long-term fund-based facilities
Assigned [ICRA]A1+ rating for Rs 218.60 crore short-term non-fund-based facilities
Total rated debt instruments amount to Rs 768.60 crore across multiple banking partners
State Bank of India holds the largest share of rated limits at Rs 230.60 crore
The 'Stable' outlook indicates ICRA's expectation of maintained credit quality in the medium term

💡 Investors should view these high investment-grade ratings as a sign of financial robustness and low credit risk. No immediate action is required, but the ratings support a positive long-term outlook for the company's capital structure.

Sai Life Sciences Allots 1.39 Lakh Equity Shares Under ESOP and MESOP Schemes

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Feb 2026, 03:58 PM

Sai Life Sciences Limited has issued a revised intimation regarding the allotment of 1,39,007 equity shares under its ESOP 2008 and MESOP 2018 plans. The revision corrects a previous omission of 10,000 shares in the earlier filing dated February 23, 2026. The company realized a total of INR 1.22 crore from the exercise of these options at various price points ranging from Rs. 23.30 to Rs. 188.90. Post-allotment, the total issued share capital of the company stands at 21,17,68,134 shares.

Total allotment of 1,39,007 equity shares of Re 1 face value each following option exercises.
Exercise prices for the shares were set at Rs. 23.30, Rs. 127.30, and Rs. 188.90 per share.
The company realized a total amount of INR 1,22,02,422.30 from the exercise of these options.
Total issued share capital has increased to 21,17,68,134 equity shares following this allotment.

💡 No action is required as this is a routine allotment of shares to employees. Investors should simply note the marginal increase in the total share count and potential minor dilution.

Sai Life Sciences Allots 1.29 Lakh Equity Shares Under ESOP Schemes

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Feb 2026, 12:31 PM

Sai Life Sciences Limited has allotted 1,29,007 equity shares of Re. 1 each to employees upon the exercise of stock options. The allotment comprises 19,007 shares under the ESOP 2008 scheme and 1,10,000 shares under the Management ESOP Plan 2018. The company realized a total of approximately Rs. 1.03 crore from these exercises. This move increases the total issued share capital to 21,17,58,134 equity shares.

Allotment of 1,29,007 equity shares following the exercise of employee stock options
Total funds realized by the company from the exercise amount to Rs. 1,03,13,422.30
Exercise prices varied between Rs. 23.30, Rs. 127.30, and Rs. 188.90 per share across different schemes
Total paid-up equity capital increased to 21,17,58,134 shares post-allotment

💡 This is a routine corporate action related to employee compensation and has no immediate impact on company fundamentals. Investors should simply note the minor equity dilution resulting from the increased share count.

Sai Life Sciences to Meet Investors at Kotak and IIFL Conferences on Feb 25-26

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Feb 2026, 03:55 PM

Sai Life Sciences Limited has scheduled meetings with institutional investors and analysts in Mumbai. The company will participate in the Kotak - Chasing Growth 2026 conference on February 25 and the IIFL 17th Entrepreneurial India Conference on February 26, 2026. These interactions will be conducted in one-on-one or group formats. The company has clarified that no unpublished price sensitive information will be shared and no new presentations will be used during these sessions.

Participation in Kotak - Chasing Growth 2026 conference on February 25, 2026.
Participation in IIFL 17th Entrepreneurial India Conference on February 26, 2026.
Meetings scheduled in Mumbai via one-on-one and group interaction formats.
Company confirmed no new presentations or unpublished price sensitive information will be disclosed.

💡 This is a routine investor engagement activity; investors should monitor for any qualitative management commentary that may emerge from these institutional interactions.

Sai Life Sciences Releases Q3 FY26 Earnings Call Transcript

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 13 Feb 2026, 02:22 PM

Sai Life Sciences has officially released the transcript for its earnings call held on February 6, 2026. The call discussed the company's unaudited financial performance for the quarter and nine-month period ending December 31, 2025. This disclosure is part of the mandatory regulatory requirements under SEBI (LODR) Regulations, 2015. The transcript provides detailed management commentary and responses to institutional investor queries regarding the company's operational trajectory.

Earnings call transcript for Q3 FY26 and 9M FY26 now available for public review
The call was originally conducted on February 6, 2026, at 4:00 PM IST
Filing complies with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)
Transcript includes detailed discussions on financial results for the period ended December 31, 2025

💡 Investors should read the transcript to gain insights into management's outlook on the CDMO sector and specific growth drivers for the upcoming fiscal year. It is a vital document for understanding the qualitative aspects of the recent financial results.

Sai Life Sciences Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 06 Feb 2026, 06:41 PM

Sai Life Sciences Limited has released the audio recording of its earnings call held on February 6, 2026. The call addressed the company's unaudited financial performance for the third quarter and the nine-month period ending December 31, 2025. This disclosure is part of the company's regulatory compliance under SEBI (LODR) Regulations, 2015. Investors can access the recording on the company's website to hear management's detailed commentary on operational results and future outlook.

Earnings call conducted on February 6, 2026, at 4:00 PM IST.
Focuses on unaudited financial results for Q3 and the nine months ended December 31, 2025.
Audio recording link provided in compliance with SEBI (LODR) Regulation 30.
Recording is publicly accessible via the company's official website link.

💡 Investors should listen to the recording to understand management's perspective on the company's financial health and strategic direction for the upcoming quarters.

Sai Life Sciences Q3 FY26 PAT Surges 86% to ₹100 Cr; EBITDA Margins Expand to 34.4%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 02:59 PM

Sai Life Sciences reported a strong performance for Q3 FY26, with consolidated revenue growing 27% YoY to ₹556 crore. The company's profitability saw a significant boost as EBITDA rose 54% to ₹191 crore, driven by a 605 bps margin expansion to 34.4%. For the nine-month period, PAT grew by a massive 199% to ₹245 crore, reflecting robust operational leverage and healthy demand in the CDMO segment. The company is aggressively investing in capacity, with ₹405 crore of the planned ₹700 crore FY26 capex already deployed.

Q3 FY26 Revenue increased 27% YoY to ₹556 crore, with CDMO services contributing 65% of total revenue.
EBITDA margins expanded significantly by 605 bps to 34.4%, outperforming the company's long-term guidance of 28-30%.
Net Profit (PAT) for the quarter jumped 86% YoY to ₹100 crore, while 9M FY26 PAT grew 199% to ₹245 crore.
Added 7 molecules to the late-phase and commercial pipeline during the year, taking the total to 43 molecules.
Invested ₹405 crore in capital expenditure out of a ₹700 crore plan for FY26 to expand manufacturing capacity by ~450KL.

💡 Investors should monitor the company's execution of its ₹700 crore capex plan and its ability to maintain margins above 30% as new capacities come online. The strong pipeline growth in late-phase molecules provides good revenue visibility for the coming years.

Sai Life Sciences Q3 FY26 PAT Jumps 86% to ₹100 Cr; 9M PAT Surges 199%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 11:21 PM

Sai Life Sciences reported a robust Q3 FY26 with revenue growing 27% YoY to ₹556 crore and PAT increasing 86% to ₹100 crore. The nine-month performance was even stronger, with PAT surging 199% to ₹245 crore on the back of 43% revenue growth. EBITDA margins expanded significantly by 605 bps to 34% in Q3, driven by improved capacity utilization and operational efficiencies. The company is on track with its ₹700 crore FY26 capex plan, having already invested ₹405 crore to enhance its CRDMO capabilities.

9M FY26 Net Profit (PAT) skyrocketed by 199% YoY to ₹245 Cr from ₹82 Cr in the previous year.
Q3 FY26 Revenue grew 27% YoY to ₹556 Cr, while EBITDA rose 54% to ₹191 Cr.
EBITDA margins expanded to 34% in Q3 FY26 compared to 28% in Q3 FY25.
Invested ₹405 Cr in capital expenditure as of date against a total FY26 plan of ₹700 Cr.
Successfully completed 8 customer audits during the quarter with zero critical observations.

💡 The company is demonstrating exceptional growth and margin expansion that outperforms broader industry trends. Investors should maintain a positive outlook while monitoring the execution of the remaining ₹300 Cr capex and the sustainability of the 30%+ EBITDA margins.

Sai Life Sciences Allots 3.97 Lakh Equity Shares Under ESOP Schemes

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Feb 2026, 09:57 PM

Sai Life Sciences has approved the allotment of 3,97,911 equity shares following the exercise of options under its 2008 and 2018 ESOP plans. The allotment consists of 22,500 shares at an exercise price of Rs. 188.90 and 3,75,411 shares at a significantly lower price of Rs. 23.30. The company realized a total of approximately Rs. 1.30 crore from this exercise. Consequently, the total paid-up equity share capital has increased to 21,16,29,127 shares.

Allotted 3,97,911 equity shares of face value Re. 1 each upon exercise of ESOPs
Total money realized from the exercise of options amounts to INR 1,29,97,326
Management ESOP Plan 2018 accounted for the bulk of the allotment with 3,75,411 shares
Total issued share capital post-allotment stands at 21,16,29,127 equity shares

💡 This is a routine corporate action involving employee compensation with minimal equity dilution. No specific action is required as this does not materially impact the company's fundamentals.

Sai Life Sciences Q3 FY26 PAT Jumps 91% YoY to ₹976.3 Million; Revenue Up 28%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 09:34 PM

Sai Life Sciences reported a robust performance for the quarter ended December 31, 2025, with revenue from operations growing 28.1% YoY to ₹5,491.79 million. Net profit surged by 91.2% YoY to ₹976.30 million, even after accounting for a one-time exceptional loss of ₹82.93 million due to new labor code liabilities. The company has successfully utilized its entire IPO proceeds of ₹9,098.84 million, primarily for debt repayment, which has significantly reduced finance costs from ₹216.59 million to ₹80.61 million YoY. Operational efficiency is reflected in the Profit Before Tax, which grew 92.1% YoY to ₹1,304.69 million.

Revenue from operations increased 28.1% YoY to ₹5,491.79 million from ₹4,286.02 million.
Net Profit (PAT) grew 91.2% YoY to ₹976.30 million compared to ₹510.57 million in the previous year.
Finance costs significantly decreased to ₹80.61 million from ₹216.59 million YoY following debt repayment.
Exceptional loss of ₹82.93 million recorded due to increased gratuity and leave liabilities under new Labour Codes.
Fully utilized IPO proceeds of ₹9,098.84 million, with ₹7,200 million used for debt repayment.

💡 The strong top-line growth and significant reduction in interest costs post-IPO debt repayment make this a positive result. Investors should monitor if the company can maintain these improved margins as it scales operations.

Sai Life Sciences Partners with Mabtech to Launch Immunology Research Hub in Boston

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 28 Jan 2026, 03:33 PM

Sai Life Sciences has announced a strategic collaboration with Swedish firm Mabtech to establish its Boston laboratory as a US execution and demonstration hub for the EYRA platform. This partnership enables Sai to offer advanced immunology assay services, including high-sensitivity multiplex cytokine and phenotyping workflows, to global biopharma clients. The EYRA platform allows for the simultaneous detection of dozens of analytes in a single run, significantly enhancing Sai's discovery and translational research capabilities. This move strengthens the company's competitive position in high-growth sectors like immuno-oncology, vaccines, and cellular therapy.

Sai’s Boston site becomes a co-marketed US execution hub for the Mabtech EYRA platform
Joint delivery of advanced immunology services targeting immuno-oncology and cellular therapy
EYRA platform enables simultaneous detection of dozens of analytes with minimal hands-on time
Strategic expansion of US discovery operations to accelerate biopharma development timelines

💡 Investors should monitor the impact of this high-tech service expansion on Sai's US revenue growth and client acquisition. This collaboration enhances the company's value proposition in the specialized CRDMO market.

Sai Life Sciences Schedules Q3FY26 Earnings Conference Call for February 6, 2026

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 28 Jan 2026, 12:14 PM

Sai Life Sciences Limited has announced its earnings conference call to discuss the un-audited financial results for the third quarter and nine months ended December 31, 2025. The call is scheduled for Friday, February 6, 2026, at 4:00 PM IST. Senior management, including MD & CEO Krishna Kanumuri and CFO Siva Chittor, will participate in the discussion and subsequent Q&A session. This event is a standard procedure for the company to provide transparency on its financial performance to the investor community.

Earnings conference call scheduled for February 6, 2026, at 4:00 PM IST
Discussion will cover un-audited financial results for Q3 and 9M ended December 31, 2025
Management representation includes MD & CEO Krishna Kanumuri and CFO Siva Chittor
International toll-free dial-in options available for USA, UK, Singapore, and Hong Kong

💡 Investors should track the financial results release on February 6 and listen to the management commentary for updates on the CRDMO project pipeline and margin outlook.

Sai Life Sciences Submits Q3 FY26 Compliance Certificate Under SEBI Regulation 74(5)

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 12 Jan 2026, 12:28 PM

Sai Life Sciences Limited has submitted its quarterly compliance certificate as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by KFin Technologies Limited, confirms that all dematerialization and rematerialization requests for the quarter ended December 31, 2025, have been processed and reported to the stock exchanges. This is a standard procedural filing required for all listed companies to ensure the integrity of shareholding records. The filing confirms that the company is in compliance with depository regulations for the period.

Compliance certificate submitted for the quarter ended December 31, 2025.
Certificate issued by KFin Technologies Limited, the company's Registrar and Share Transfer Agent (RTA).
Confirms that details of securities dematerialized/rematerialized have been furnished to BSE and NSE.
Filing is in accordance with SEBI (Depositories and Participants) Regulations, 2018.

💡 This is a routine regulatory disclosure with no impact on the company's financial performance or business operations. No action is required from investors.

Sai Life Sciences Receives Warning Letters from NSE and BSE for FY25 Governance Non-Compliance

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 07 Jan 2026, 05:25 PM

Sai Life Sciences Limited has received formal warning letters from both BSE and NSE regarding non-compliance with SEBI Listing Obligations and Disclosure Requirements (LODR) for the financial year ended March 31, 2025. The violation pertains to Regulation 20(3A), which requires the Stakeholders’ Relationship Committee (SRC) to meet at least once per financial year. The company clarified that no meeting was held because it only listed on December 18, 2024, leaving a short window of approximately 100 days in the financial year with no urgent agenda items. The exchanges have advised the company to exercise caution, though the company confirms no material financial or operational impact.

Received warning letters from BSE dated January 6, 2026, and NSE dated January 7, 2026.
Non-compliance identified regarding the failure to hold a Stakeholders’ Relationship Committee meeting in FY 2024-25.
Company listed on stock exchanges on December 18, 2024, resulting in a short operational period for the reported financial year.
Management states there is no material impact on financial, operational, or other activities of the company.
The exchanges have warned of serious action for any future aberrations regarding SEBI LODR compliance.

💡 Investors should treat this as a minor procedural lapse typical of newly listed entities and monitor future governance reports for consistent compliance. No immediate portfolio action is necessary as no financial penalties were levied.

View All SAILIFE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In H1 FY26, the CDMO segment grew 72% YoY to INR 667 Cr, contributing 64% of total revenue. The CRO segment grew 28% YoY to INR 367 Cr, contributing 36% of total revenue. For the full FY 2024-25, total income grew 15.9% YoY to INR 1,731.35 Cr.

Geographic Revenue Split

The company serves 300+ global clients across the US, UK, EU, and Japan, though specific percentage splits per region are not disclosed in the available documents.

Profitability Margins

Gross margins expanded in FY25 due to operational efficiencies in commercial products. PAT margin expanded 430 bps to 10.0% in FY25 (INR 170.13 Cr) from 5.7% in FY24. In H1 FY26, PAT stood at INR 144 Cr.

EBITDA Margin

EBITDA margin was 25.0% in FY25 (INR 424.74 Cr), up 460 bps from 20.4% in FY24. Margins further improved to 27% in H1 FY26 and reached 29% (INR 156 Cr) in Q2 FY26 due to operating leverage and better capacity utilization.

Capital Expenditure

The company incurred INR 248 Cr in capex during H1 FY26, primarily for R&D capacity expansion, against a total planned capex of INR 700 Cr for the full FY26.

Credit Rating & Borrowing

Finance costs decreased by 11.3% YoY to INR 76.16 Cr in FY25, primarily driven by the repayment of INR 720 Cr of debt using IPO proceeds.

⚙️ Operational Drivers

Raw Materials

Specific chemical names are not disclosed; however, Cost of Goods Sold (COGS) represented 26.9% of total income in FY25, amounting to INR 465.76 Cr.

Capacity Expansion

The company is expanding R&D capacity and advancing offerings in new modalities. Current capacity utilization was reported at 67% for FY 2024-25.

Raw Material Costs

COGS increased by 4.5% YoY to INR 465.76 Cr in FY25, a slower rate than revenue growth, leading to a 290 bps increase in gross margins due to operational efficiencies in commercial products.

Manufacturing Efficiency

Capacity utilization stood at 67% in FY25. Efficiency gains in commercial product manufacturing were cited as the primary driver for gross margin expansion.

📈 Strategic Growth

Expected Growth Rate

15-20%

Growth Strategy

Growth is driven by an integrated CRDMO model that provides seamless support from discovery to commercial manufacturing. The strategy includes scaling late-stage and commercial programs (3 products recently moved to late-stage) and investing INR 700 Cr in FY26 for R&D and new technology capacity.

Products & Services

The company provides CRO (Discovery) and CDMO (Development and Manufacturing) services, including CMC (Chemistry, Manufacturing, and Controls) and integrated drug discovery services.

Brand Portfolio

Sai Life Sciences

New Products/Services

The company is advancing offerings in new modalities and technologies; 3 products recently transitioned into the late-stage pipeline, which typically drives higher revenue as they move toward commercialization.

Market Expansion

Expansion is focused on global pharma hubs in the US, UK, EU, and Japan, leveraging world-class facilities in Hyderabad, Bidar, and Manchester.

Strategic Alliances

Maintains a 5-year strategic partnership with Schrödinger (signed in 2023) focused on drug discovery candidates.

🌍 External Factors

Industry Trends

The industry is seeing a continued shift toward outsourcing by global pharma to integrated CRDMOs. Sai Life Sciences is positioning itself to capture this by expanding its late-stage pipeline and R&D capabilities.

Competitive Landscape

Competes with global CRDMOs; the company uses top-tier consulting firms to benchmark its productivity and cost structure against global peers.

Competitive Moat

The moat is built on 25+ years of expertise, an integrated 'Discovery to Delivery' model, and deep-rooted relationships with 18 of the top 25 global pharma firms, which creates high switching costs.

Macro Economic Sensitivity

The business is sensitive to global pharmaceutical R&D spending and macroeconomic trends affecting biotech venture capital funding.

Geopolitical Risks

Operations across India and the UK expose the company to international regulatory shifts and trade policies in the pharma sector.

⚖️ Regulatory & Governance

Industry Regulations

The company maintains cost records as mandated under Section 148(1) of the Companies Act, 2013. It must comply with stringent manufacturing standards for global pharma supply.

Taxation Policy Impact

The consolidated effective tax rate for FY 2024-25 was 25.3%, with a total tax expense of INR 57.57 Cr.

Legal Contingencies

An order was passed under Section 73(9) of the Goods and Services Tax Act by the Deputy Commissioner of Commercial Taxes (Audit), Bidar, regarding tax matters.

⚠️ Risk Analysis

Key Uncertainties

Biotech funding volatility poses a risk to the CRO segment's growth. Operational risks are managed through a Vigil Mechanism and a Code of Conduct for Board and Senior Management.